Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?

Megan C. Turner, Kara Rossfeld, April K.S. Salama, Douglas Tyler, Georgia Beasley

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Fingerprint

Dive into the research topics of 'Can binimetinib, encorafenib and masitinib be more efficacious than currently available mutation-based targeted therapies for melanoma treatment?'. Together they form a unique fingerprint.

Medicine & Life Sciences